[P02BB01, trichlorfon, The therapeutic efficacy of Methadone can be decreased when used in combination with Metrifonate.]
[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Methadone.]
[J01GA01, streptomycin, Methadone may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Methadone is combined with Succinylcholine.]
[A02BX02, sucralfate, Methadone may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Methadone may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The metabolism of Methadone can be decreased when combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Methadone can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The metabolism of Methadone can be decreased when combined with Sulfamethoxazole.]
[J01EC03, sulfamoxole, The metabolism of Methadone can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Methadone can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Methadone can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Methadone.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Methadone is combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Methadone is combined with Sulthiame.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Methadone.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N06DA01, tacrine, The therapeutic efficacy of Methadone can be decreased when used in combination with Tacrine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Methadone.]
[N05CD07, temazepam, Temazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Methadone.]
[R03CC03, terbutaline, The therapeutic efficacy of Methadone can be decreased when used in combination with Terbutaline.]
[B01AE07, dabigatran etexilate, Methadone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Methadone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Methadone is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Methadone is combined with Tetracaine.]
[S03AA02, tetracycline, Methadone may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Methadone is combined with Lurasidone.]
[A04AD10, dronabinol, The risk or severity of adverse effects can be increased when Methadone is combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Methadone is combined with Apomorphine.]
[L04AX02, thalidomide, Methadone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Methadone.]
[P02CA02, thiabendazole, Methadone may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Methadone.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Methadone is combined with Thiethylperazine.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Methadone.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Methadone is combined with Thiopental.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Methadone is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Methadone is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Methadone is combined with Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Methadone.]
[B02AB01, aprotinin, The therapeutic efficacy of Methadone can be decreased when used in combination with Aprotinin.]
[G04BE06, moxisylyte, Methadone may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Methadone is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Methadone can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Methadone is combined with Tilidine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Methadone.]
[P01AB02, tinidazole, Methadone may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Methadone may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Methadone may decrease the excretion rate of Tolazamide which could result in a higher serum level.]
[V04CA01, tolbutamide, Methadone may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Methadone is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of adverse effects can be increased when Methadone is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Methadone.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Methadone is combined with Trazodone.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Methadone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, The risk or severity of adverse effects can be increased when Mepenzolate is combined with Methadone.]
[S01EB04, demecarium, The therapeutic efficacy of Methadone can be decreased when used in combination with Demecarium.]
[A16AX12, trientine, Methadone may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Methadone is combined with Trifluoperazine.]
[S01AD02, trifluridine, Methadone may decrease the excretion rate of Trifluridine which could result in a higher serum level.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Methadone is combined with Trifluperidol.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Methadone is combined with Triflupromazine.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Methadone.]
[A03AA05, trimebutine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Methadone.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Methadone is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Methadone is combined with Trimethadione.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Trimethaphan is combined with Methadone.]
[J01EA01, trimethoprim, Methadone may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Methadone is combined with Trimipramine.]
[R06AC04, tripelennamine, The metabolism of Methadone can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Methadone is combined with Triprolidine.]
[A03BB01, butylscopolamine, The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Methadone.]
[J01FA08, troleandomycin, The metabolism of Methadone can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Methadone is combined with Vilazodone.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Methadone is combined with Tropicamide.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Methadone is combined with Tryptophan.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Methadone is combined with Tubocurarine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Methadone.]
[L01FX04, ipilimumab, Methadone may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[S01AA05, tyrothricin, The therapeutic efficacy of Methadone can be decreased when used in combination with Tyrothricin.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Methadone.]
[R02AA14, oxyquinoline, Methadone may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Methadone can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Methadone can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Methadone can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Methadone can be decreased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Methadone can be decreased when it is combined with Rilpivirine.]
[S01AA28, vancomycin, Methadone may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Methadone is combined with Ezogabine.]
[B01AF01, rivaroxaban, Methadone may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Methadone.]
[B01AC24, ticagrelor, Methadone can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08DA01, verapamil, The metabolism of Methadone can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Methadone is combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Methadone.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Methadone.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Methadone.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Methadone.]
[S01AA13, fusidic acid, The metabolism of Methadone can be decreased when combined with Fusidic acid.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The serum concentration of Zidovudine can be increased when it is combined with Methadone.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Methadone is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Methadone can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Methadone is combined with Levetiracetam.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be decreased when combined with Methadone.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Methadone.]
[M05BA05, tiludronic acid, Methadone may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Methadone may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Methadone.]
[R03DC01, zafirlukast, The metabolism of Methadone can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Methadone can be decreased when combined with Rabeprazole.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Methadone.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Methadone is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Methadone is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Methadone may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Methadone.]
[G04BD07, tolterodine, The risk or severity of adverse effects can be increased when Tolterodine is combined with Methadone.]
[J01DH04, doripenem, Methadone may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The metabolism of Atenolol can be decreased when combined with Methadone.]
[L03AB11, peginterferon alfa-2a, The serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2a.]
[J02AC03, voriconazole, The serum concentration of Methadone can be increased when it is combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Methadone is combined with Atracurium.]
[S01FA01, atropine, The risk or severity of adverse effects can be increased when Atropine is combined with Methadone.]
[M01CB03, auranofin, Methadone may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Methadone.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Methadone.]
[B03XA04, peginesatide, Methadone may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Methadone may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Methadone may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Methadone may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01DF01, aztreonam, Methadone may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Methadone.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Methadone is combined with Baclofen.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Methadone is combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Methadone can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The serum concentration of Methadone can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Methadone can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Methadone can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Methadone.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Methadone.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Methadone.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Methadone is combined with Barbital.]
[D02BA02, octinoxate, Methadone may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The serum concentration of Methadone can be decreased when it is combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[N04BD02, rasagiline, The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Methadone.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Methadone is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Methadone is combined with Donepezil.]
[N03AX22, perampanel, The risk or severity of adverse effects can be increased when Methadone is combined with Perampanel.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Methadone.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Methadone is combined with Zolmitriptan.]
[R06AC06, thonzylamine, The risk or severity of adverse effects can be increased when Thonzylamine is combined with Methadone.]
[G04BD10, darifenacin, The risk or severity of adverse effects can be increased when Darifenacin is combined with Methadone.]
[V09IX04, fluorodeoxyglucose F18, Methadone may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Methadone is combined with Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Methadone.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Methadone.]
[G04BE03, sildenafil, The metabolism of Methadone can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Methadone may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Methadone.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Methadone.]
[A16AX08, teduglutide, Methadone may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Methadone.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Methadone is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Methadone.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Methadone.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Methadone can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Methadone is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Methadone.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Methadone is combined with Benperidol.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Methadone is combined with Gemifloxacin.]
[M04AB03, benzbromarone, The metabolism of Methadone can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Methadone.]
[A06AX06, tegaserod, The metabolism of Methadone can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Methadone is combined with Benzocaine.]
[L03AA12, ancestim, Methadone may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The metabolism of Methadone can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Methadone is combined with Naratriptan.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Methadone.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Benzatropine is combined with Methadone.]
[L01EC02, dabrafenib, The serum concentration of Methadone can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L01EE01, trametinib, Methadone may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Methadone is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Methadone may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Methadone is combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Methadone is combined with Bepridil.]
[A10BJ03, lixisenatide, Methadone may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Methadone may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Methadone.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Methadone is combined with Vortioxetine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Methadone is combined with Eslicarbazepine.]
[D01AC18, luliconazole, The serum concentration of Methadone can be increased when it is combined with Luliconazole.]
[J05AP05, simeprevir, The metabolism of Methadone can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Methadone may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Methadone is combined with Vigabatrin.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Methadone may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, The metabolism of Acebutolol can be decreased when combined with Methadone.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Methadone is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Methadone can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Methadone can be increased when combined with Apremilast.]
[L02BG02, formestane, The serum concentration of Methadone can be increased when it is combined with Formestane.]
[A16AA06, betaine, The therapeutic efficacy of Methadone can be decreased when used in combination with Betaine.]
[S03BA03, betamethasone, The metabolism of Methadone can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Methadone.]
[V03AB34, fomepizole, Methadone may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[L04AC11, siltuximab, The metabolism of Methadone can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Methadone.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Methadone.]
[A03BA03, hyoscyamine, The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Methadone.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Methadone.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Methadone.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Methadone is combined with Alfaxalone.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Methadone.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Methadone which could result in a higher serum level.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Methadone.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N05CM19, suvorexant, The risk or severity of adverse effects can be increased when Methadone is combined with Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Methadone.]
[J01XA05, oritavancin, The metabolism of Methadone can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Methadone is combined with Acepromazine.]
[V04CX03, methacholine, Methadone may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Methadone.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Methadone is combined with Naloxegol.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Biperiden is combined with Methadone.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Methadone.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Methadone.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Methadone.]
[S03AA06, gentamicin, Methadone may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Methadone.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Methadone.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Methadone is combined with Dicoumarol.]
[B01AF03, edoxaban, Methadone may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, The risk or severity of adverse effects can be increased when Methadone is combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Methadone can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Methadone.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Methadone is combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Methadone can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Methadone.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[A03AA09, difemerine, The risk or severity of adverse effects can be increased when Difemerine is combined with Methadone.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Methadone is combined with Tioclomarol.]
[C01EB17, ivabradine, Ivabradine may increase the QTc-prolonging activities of Methadone.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Methadone can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Methadone is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Methadone is combined with Brexpiprazole.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Methadone.]
[A04AD14, rolapitant, The metabolism of Methadone can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Methadone is combined with Flibanserin.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Methadone.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Methadone is combined with Cariprazine.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Methadone which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Methadone is combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Methadone is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Methadone can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Methadone may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Methadone.]
[J02AC05, isavuconazole, The metabolism of Methadone can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Methadone.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Methadone.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Methadone.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Methadone.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Methadone.]
[A10BB31, acetohexamide, The metabolism of Acetohexamide can be decreased when combined with Methadone.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Methadone.]
[M04AB05, lesinurad, Methadone may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Methadone is combined with Aprobarbital.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Methadone is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Methadone.]
[N05BA08, bromazepam, Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Methadone is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Methadone may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Methadone is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Methadone is combined with Dexbrompheniramine.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Methadone is combined with Amineptine.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Methadone.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Methadone is combined with Aniracetam.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Methadone is combined with Bupivacaine.]
[C07AA19, bupranolol, The metabolism of Bupranolol can be decreased when combined with Methadone.]
[N07BC01, buprenorphine, The risk or severity of adverse effects can be increased when Methadone is combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Methadone.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Methadone is combined with Buspirone.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Methadone.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Methadone is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, The therapeutic efficacy of Methadone can be decreased when used in combination with Rivastigmine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Methadone is combined with Artemether.]
[M02AA03, clofezone, The metabolism of Methadone can be decreased when combined with Rabeprazole.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Methadone is combined with Butorphanol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Methadone is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Methadone.]
[S01GX07, azelastine, The risk or severity of adverse effects can be increased when Methadone is combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Methadone can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Methadone.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Methadone.]
[L01EF02, ribociclib, The metabolism of Methadone can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Methadone which could result in a higher serum level.]
[R03CC12, bambuterol, The therapeutic efficacy of Methadone can be decreased when used in combination with Bambuterol.]
[A06AH05, naldemedine, The therapeutic efficacy of Methadone can be decreased when used in combination with Naldemedine.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Methadone is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of adverse effects can be increased when Methadone is combined with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Methadone is combined with Beclamide.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Methadone is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Methadone may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Methadone.]
[J05AF06, abacavir, The therapeutic efficacy of Abacavir can be decreased when used in combination with Methadone.]
[J05AE09, tipranavir, The metabolism of Methadone can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Methadone.]
[L04AB02, infliximab, The metabolism of Methadone can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Methadone can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Methadone.]
[N04BD03, safinamide, The risk or severity of serotonin syndrome can be increased when Safinamide is combined with Methadone.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Methadone.]
[L01BC06, capecitabine, The metabolism of Methadone can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Methadone.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Methadone.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Methadone.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Methadone.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Methadone.]
[C07AB07, bisoprolol, Methadone may decrease the excretion rate of Bisoprolol which could result in a higher serum level.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Methadone is combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Methadone.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Bornaprine is combined with Methadone.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Methadone is combined with Bromperidol.]
[N05CD09, brotizolam, Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Methadone may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Methadone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Methadone is combined with Butobarbital.]
[J05AX18, letermovir, The metabolism of Methadone can be increased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Methadone is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Methadone.]
[N01BX04, capsaicin, The therapeutic efficacy of Methadone can be decreased when used in combination with Capsaicin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Methadone is combined with Vinylbital.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Methadone.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Methadone is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Methadone can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Methadone can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Methadone.]
[A03AA03, camylofine, The risk or severity of adverse effects can be increased when Camylofin is combined with Methadone.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Methadone is combined with Carbinoxamine.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Methadone.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Methadone is combined with Cannabidiol.]
[B02BX08, avatrombopag, The metabolism of Methadone can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, Methadone may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Methadone is combined with Encorafenib.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01GB14, plazomicin, Methadone may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The metabolism of Celiprolol can be decreased when combined with Methadone.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Methadone.]
[L01XX62, ivosidenib, The metabolism of Methadone can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Methadone.]
[A16AX14, migalastat, Methadone may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Methadone is combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Methadone can be decreased when combined with Tecovirimat.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Methadone.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Methadone.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Methadone is combined with Cetirizine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Methadone is combined with Carbromal.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Methadone.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Methadone is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Methadone may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Methadone.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Methadone.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Methadone is combined with Carisoprodol.]
[R03BB08, revefenacin, The risk or severity of adverse effects can be increased when Revefenacin is combined with Methadone.]
[L04AA39, emapalumab, The metabolism of Methadone can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L01EX13, gilteritinib, The therapeutic efficacy of Methadone can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Methadone is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Methadone is combined with Amifampridine.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Methadone.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Methadone.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Methadone.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Methadone is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Methadone can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Methadone is combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Methadone.]
[J01FA09, clarithromycin, The metabolism of Methadone can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Methadone is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Methadone is combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Methadone.]
[N05BA09, clobazam, Clobazam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Methadone.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[C09CA06, candesartan, The metabolism of Methadone can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Methadone can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The serum concentration of Methadone can be decreased when it is combined with Alpelisib.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Methadone.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Methadone is combined with Cyamemazine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Methadone which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Methadone which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of adverse effects can be increased when Methadone is combined with Cyclobenzaprine.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Methadone.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Methadone is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Methadone can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Methadone.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Methadone.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Methadone.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Methadone is combined with Yohimbine.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Methadone.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Methadone.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Methadone.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Methadone is combined with Lasmiditan.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Methadone.]
[G03AC09, desogestrel, The metabolism of Methadone can be decreased when combined with Desogestrel.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Methadone.]
[N03AX25, cenobamate, The serum concentration of Methadone can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Methadone can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Methadone may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Methadone is combined with Dexbrompheniramine.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Methadone is combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Methadone may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Methadone is combined with Dezocine.]
[L01EX18, avapritinib, The metabolism of Methadone can be decreased when combined with Avapritinib.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Methadone is combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Methadone.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Methadone is combined with Lumateperone.]
[M01AX21, diacetylrhein, The metabolism of Methadone can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Methadone.]
[H02CA02, osilodrostat, The metabolism of Methadone can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The serum concentration of the active metabolites of Amprenavir can be reduced when Amprenavir is used in combination with Methadone resulting in a loss in efficacy.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Methadone is combined with Frovatriptan.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Methadone is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Methadone.]
[R02AA03, dichlorobenzyl alcohol, Methadone may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Methadone may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Methadone is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Methadone is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Methadone is combined with Eletriptan.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L01XF03, bexarotene, The metabolism of Methadone can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Methadone can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Methadone can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Methadone is combined with Valpromide.]
[S03AA08, chloramphenicol, The metabolism of Methadone can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Methadone.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Methadone.]
[A03AA08, dihexyverine, The risk or severity of adverse effects can be increased when Dihexyverine is combined with Methadone.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be increased when it is combined with Methadone.]
[P01BE01, artemisinin, The metabolism of Artemisinin can be decreased when combined with Methadone.]
[G04BD09, trospium, The risk or severity of adverse effects can be increased when Trospium is combined with Methadone.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Methadone which could result in a higher serum level.]
[V08CA05, mangafodipir, Methadone may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be increased when it is combined with Methadone.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Methadone is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Methadone is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Methadone is combined with Dyclonine.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Methadone.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Methadone.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Methadone.]
[N05CD14, remimazolam, Remimazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[L04AC19, satralizumab, The serum concentration of Methadone can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of adverse effects can be increased when Methadone is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Methadone can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Methadone can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Methadone is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of adverse effects can be increased when Methadone is combined with Chlorpromazine.]
[A10BB02, chlorpropamide, Methadone may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.]
[N05AF03, chlorprothixene, The risk or severity of adverse effects can be increased when Methadone is combined with Chlorprothixene.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Methadone is combined with Chlorzoxazone.]
[A11CC05, cholecalciferol, The metabolism of Methadone can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Methadone is combined with Etifoxine.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N02BA03, choline salicylate, Methadone may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Methadone is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Methadone which could result in a higher serum level.]
[M02AA06, etofenamate, The therapeutic efficacy of Etofenamate can be decreased when used in combination with Methadone.]
[B06AC06, berotralstat, The metabolism of Methadone can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Methadone can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Methadone.]
[M01AX25, chondroitin sulfates, Methadone may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[P03AX07, abametapir, The serum concentration of Methadone can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Methadone can be decreased when combined with Tepotinib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Methadone is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Methadone is combined with Felbamate.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C01CA19, fenoldopam, Methadone may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[J01DD15, cefdinir, Methadone may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Methadone.]
[S02BA08, fluocinolone acetonide, Methadone may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.]
[N02BG07, flupirtine, Methadone may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Methadone.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Methadone.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Methadone is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The metabolism of Methadone can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Methadone is combined with Gabapentin.]
[V08CA04, gadoteridol, Methadone may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Methadone is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Methadone is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Methadone can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Methadone.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Methadone is combined with Ciprofloxacin.]
[L01XA01, cisplatin, Methadone may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Methadone is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Methadone can be decreased when combined with Somapacitan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Methadone.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Methadone is combined with Fexinidazole.]
[L01XX74, belzutifan, The metabolism of Belzutifan can be decreased when combined with Methadone.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Methadone is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Methadone may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Methadone may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Methadone may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Methadone is combined with Clemastine.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Methadone which could result in a higher serum level.]
[A10BB12, glimepiride, The metabolism of Methadone can be decreased when combined with Glimepiride.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Methadone.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Methadone.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Methadone is combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Methadone can be decreased when combined with Asciminib.]
[L02BG06, exemestane, The serum concentration of Methadone can be increased when it is combined with Exemestane.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Methadone.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Methadone.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Methadone.]
[B06AX04, mitapivat, The metabolism of Methadone can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Methadone is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Methadone.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Methadone is combined with Clomipramine.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Methadone is combined with Clonidine.]
[C01EB24, mavacamten, The serum concentration of Methadone can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC08, vonoprazan, The metabolism of Methadone can be decreased when combined with Vonoprazan.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Methadone is combined with Clothiapine.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Methadone is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Methadone is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of adverse effects can be increased when Methadone is combined with Clozapine.]
[J01GB12, arbekacin, Methadone may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[H01AC08, somatrogon, The metabolism of Methadone can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of adverse effects can be increased when Cocaine is combined with Methadone.]
[C02KB01, metyrosine, Methadone may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Methadone can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Methadone which could result in a higher serum level.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Methadone is combined with Codeine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Methadone is combined with Hexafluronium.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Methadone.]
[A03AB10, hexocyclium, The risk or severity of adverse effects can be increased when Hexocyclium is combined with Methadone.]
[A03BB06, homatropine methylbromide, The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Methadone.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Methadone is combined with Homatropine.]
[J01XB01, colistin, Methadone may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L04AA13, leflunomide, The metabolism of Methadone can be decreased when combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Methadone is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Methadone is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Methadone is combined with Ifenprodil.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Methadone.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01FA15, telithromycin, The metabolism of Methadone can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Methadone.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Methadone which could result in a higher serum level.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Methadone is combined with Desloratadine.]
[J05AB14, valganciclovir, Methadone may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Methadone may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Methadone may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Methadone may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Methadone may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Methadone may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Methadone which could result in a higher serum level.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadone.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Methadone is combined with Almotriptan.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J02AC02, itraconazole, The serum concentration of Methadone can be increased when it is combined with Itraconazole.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Methadone which could result in a higher serum level.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Methadone is combined with Emedastine.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L01EA01, imatinib, The serum concentration of Methadone can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Methadone can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Methadone can be decreased when combined with Esomeprazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Methadone.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Methadone.]
[N03AX09, lamotrigine, The risk or severity of adverse effects can be increased when Methadone is combined with Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of adverse effects can be increased when Methadone is combined with Levocabastine.]
[N07BC04, lofexidine, The risk or severity of adverse effects can be increased when Methadone is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Methadone is combined with Lomefloxacin.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Methadone which could result in a higher serum level.]
[R06AX13, loratadine, Methadone may increase the anticholinergic activities of Loratadine.]
[N05CD06, lormetazepam, Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C09AA03, lisinopril, Methadone may decrease the excretion rate of Lisinopril which could result in a higher serum level.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Methadone.]
[C08CA11, manidipine, The metabolism of Methadone can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The risk or severity of adverse effects can be increased when Mebeverine is combined with Methadone.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Methadone is combined with Medifoxamine.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Methadone.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be decreased when combined with Methadone.]
[J01DH02, meropenem, Methadone may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Methadone is combined with Adenosine.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Metixene is combined with Methadone.]
[R03CB02, methoxyphenamine, Methoxyphenamine may increase the analgesic activities of Methadone.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Methadone is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Methadone is combined with Cyclobarbital.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Methadone is combined with Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Methadone is combined with Cyclopentolate.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Methadone.]
[N06AX07, minaprine, The risk or severity of serotonin syndrome can be increased when Minaprine is combined with Methadone.]
[S01XA18, cyclosporine, The metabolism of Methadone can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of serotonin syndrome can be increased when Moclobemide is combined with Methadone.]
[N06BA07, modafinil, The metabolism of Methadone can be decreased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of adverse effects can be increased when Methadone is combined with Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Methadone.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Methadone.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Methadone which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Methadone can be decreased when combined with Conivaptan.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Methadone.]
[M01AH05, etoricoxib, The metabolism of Methadone can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, Methadone may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[G03XA01, danazol, The metabolism of Methadone can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Methadone is combined with Dantrolene.]
[J04BA02, dapsone, The metabolism of Methadone can be decreased when combined with Dapsone.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Methadone is combined with Deanol.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Methadone.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Methadone is combined with Nabilone.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N07BB05, nalmefene, The therapeutic efficacy of Methadone can be decreased when used in combination with Nalmefene.]
[B05XA15, potassium lactate, The therapeutic efficacy of Potassium lactate can be decreased when used in combination with Methadone.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Methadone.]
[S01GX04, nedocromil, Methadone may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Methadone is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Methadone is combined with Niaprazine.]
[C01DX16, nicorandil, Methadone may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, The metabolism of Methadone can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Methadone is combined with Tiagabine.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Methadone is combined with Cisatracurium.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Methadone is combined with Normethadone.]
[B01AX05, fondaparinux, Methadone may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Methadone is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of adverse effects can be increased when Solifenacin is combined with Methadone.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N06AA01, desipramine, The risk or severity of adverse effects can be increased when Methadone is combined with Desipramine.]
[H01BA02, desmopressin, The risk or severity of hyponatremia can be increased when Methadone is combined with Desmopressin.]
[V04CH02, indigo carmine, Methadone may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Methadone is combined with Oxaliplatin.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Methadone is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Methadone can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Methadone is combined with Oxiracetam.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Dexetimide is combined with Methadone.]
[G04BD04, oxybutynin, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Methadone.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Methadone.]
[A03AA01, oxyphencyclimine, The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Methadone.]
[L04AB04, adalimumab, The metabolism of Methadone can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Methadone.]
[N06BA02, dextroamphetamine, Amphetamine may increase the analgesic activities of Methadone.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Methadone is combined with Dextromethorphan.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Methadone is combined with Paramethadione.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Methadone is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Methadone is combined with Paroxetine.]
[B01AC04, clopidogrel, Methadone can cause a decrease in the absorption of Clopidogrel resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Methadone is combined with Diamorphine.]
[P03AC04, permethrin, Methadone may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Methadone is combined with Phenacemide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Methadone is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Methadone is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Methadone is combined with Cinchocaine.]
[R05DA08, pholcodine, Methadone may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Methadone.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Methadone.]
[A03AA07, dicyclomine, The risk or severity of adverse effects can be increased when Dicyclomine is combined with Methadone.]
[J05AF02, didanosine, The serum concentration of Didanosine can be decreased when it is combined with Methadone.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Methadone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Methadone is combined with Pipamperone.]
[A03AB14, pipenzolate, The risk or severity of adverse effects can be increased when Pipenzolate is combined with Methadone.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Methadone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Methadone.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Methadone can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Methadone is combined with Diethylpropion.]
[L02AA01, diethylstilbestrol, The metabolism of Methadone can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Methadone can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, Methadone may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, The risk or severity of adverse effects can be increased when Poldine is combined with Methadone.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Methadone.]
[C01AA05, digoxin, Methadone may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Methadone.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Methadone is combined with Dihydroergotamine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Methadone is combined with Hydromorphone.]
[L04AX04, lenalidomide, Methadone may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Methadone can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Methadone.]
[H03BC01, potassium perchlorate, Methadone may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Methadone may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Methadone is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Methadone is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Methadone is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Methadone may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Methadone is combined with Pridinol.]
[R06AB03, dimethindene, The risk or severity of adverse effects can be increased when Dimetindene is combined with Methadone.]
[M02AX03, dimethyl sulfoxide, The metabolism of Methadone can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Methadone is combined with Progabide.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Methadone which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C05CA03, diosmin, The metabolism of Methadone can be decreased when combined with Diosmin.]
[R06AA02, diphenhydramine, The risk or severity of adverse effects can be increased when Methadone is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Methadone is combined with Diphenoxylate.]
[N05CD10, quazepam, Quazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Methadone is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Methadone is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Methadone is combined with Cisapride.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Methadone.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Methadone is combined with Remoxipride.]
[S01AX06, resorcinol, Methadone may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Methadone.]
[N07AA03, distigmine, The therapeutic efficacy of Methadone can be decreased when used in combination with Distigmine.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Methadone.]
[S02AA12, rifamycin SV, The metabolism of Methadone can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Methadone can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Methadone is combined with Riluzole.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Methadone is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Methadone is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Methadone is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Methadone.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Methadone.]
[A04AD12, aprepitant, The metabolism of Methadone can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Methadone.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Methadone.]
[J05AE07, fosamprenavir, The serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Methadone resulting in a loss in efficacy.]
[G04BE08, tadalafil, Methadone may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C01EB18, ranolazine, The serum concentration of Methadone can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Methadone which could result in a higher serum level.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Methadone.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C01CA07, dobutamine, Methadone may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Methadone is combined with Domperidone.]
[C01CA04, dopamine, Methadone may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA16, dothiepin, The risk or severity of adverse effects can be increased when Methadone is combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of adverse effects can be increased when Methadone is combined with Doxepin.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Methadone.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Methadone.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Methadone which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of adverse effects can be increased when Methadone is combined with Doxylamine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Methadone is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Methadone is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of adverse effects can be increased when Methadone is combined with Droperidol.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Methadone is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Methadone.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Methadone.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Methadone.]
[R03DA01, dyphylline, Methadone may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Methadone is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Methadone is combined with Sumatriptan.]
[V04CX07, edrophonium, The therapeutic efficacy of Methadone can be decreased when used in combination with Edrophonium.]
[C07AB13, talinolol, The metabolism of Talinolol can be decreased when combined with Methadone.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Methadone is combined with Temafloxacin.]
[L01AX03, temozolomide, Methadone may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Methadone which could result in a higher serum level.]
[D01BA02, terbinafine, The metabolism of Methadone can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Methadone is combined with Terodiline.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Methadone.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Methadone is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Methadone is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Methadone is combined with Thiopropazate.]
[G04BD01, emepronium, The risk or severity of adverse effects can be increased when Methadone is combined with Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Methadone is combined with Tianeptine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Methadone is combined with Tofisopam.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N06AG03, toloxatone, The risk or severity of serotonin syndrome can be increased when Toloxatone is combined with Methadone.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Methadone.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Methadone is combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Methadone is combined with Toremifene.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD11, triazulenone, Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Methadone is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Methadone is combined with Triclofos.]
[A03AB08, tridihexethyl, The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Methadone.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Methadone is combined with Trimethobenzamide.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Methadone.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Tropatepine is combined with Methadone.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Methadone is combined with Enflurane.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Methadone is combined with Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Methadone.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Methadone is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Methadone.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Methadone is combined with Epinastine.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Methadone is combined with Venlafaxine.]
[C08CA12, mepirodipine, The metabolism of Methadone can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Methadone can be decreased when combined with Epinephrine.]
[N05CF02, zolpidem, The risk or severity of adverse effects can be increased when Methadone is combined with Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Methadone is combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Methadone is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Methadone is combined with Zotepine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Methadone is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Methadone is combined with Moricizine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Methadone is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Methadone is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Methadone is combined with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Methadone is combined with Valproic acid.]
[L03AX05, pidotimod, Methadone may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Methadone.]
[N05CD04, estazolam, Estazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[A02BC02, pantoprazole, The metabolism of Methadone can be decreased when combined with Pantoprazole.]
[H05BX01, cinacalcet, The metabolism of Methadone can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Methadone.]
[J04AK02, ethambutol, The metabolism of Methadone can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Methadone.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C01CA15, gepefrine, Gepefrine may increase the analgesic activities of Methadone.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Methadone is combined with Ethchlorvynol.]
[L02AA03, ethinyl estradiol, The metabolism of Methadone can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Methadone is combined with Ibutilide.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Methadone.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Methadone is combined with Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Methadone is combined with Ethotoin.]
[M01AC06, meloxicam, Meloxicam may decrease the excretion rate of Methadone which could result in a higher serum level.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Methadone is combined with Ethylmorphine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Methadone is combined with Etomidate.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Methadone.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Methadone is combined with Sertindole.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Methadone.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Methadone.]
[A02BA04, nizatidine, The therapeutic efficacy of Methadone can be decreased when used in combination with Nizatidine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Methadone.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Methadone.]
[R06AX12, terfenadine, The metabolism of Methadone can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Methadone may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Methadone is combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Methadone is combined with Fluvoxamine.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Methadone.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Methadone.]
[M01CB01, gold sodium thiomalate, Methadone may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Methadone may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Methadone may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Methadone.]
[A16AA01, levocarnitine, Methadone may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Methadone.]
[C08CA02, felodipine, The metabolism of Methadone can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Methadone is combined with Fendiline.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Methadone is combined with Fenfluramine.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Methadone which could result in a higher serum level.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Fenoterol is combined with Methadone.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Methadone.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Methadone.]
[L01BB06, clofarabine, Methadone may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Methadone.]
[G04BD02, flavoxate, The risk or severity of adverse effects can be increased when Flavoxate is combined with Methadone.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Methadone.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J02AC01, fluconazole, The metabolism of Methadone can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Methadone may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Methadone may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Methadone is combined with Flunarizine.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Methadone is combined with Melitracen.]
[V03AZ01, ethanol, The risk or severity of adverse effects can be increased when Methadone is combined with Ethanol.]
[L01BC09, floxuridine, The metabolism of Methadone can be decreased when combined with Floxuridine.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Methadone is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of adverse effects can be increased when Methadone is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of adverse effects can be increased when Methadone is combined with Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Methadone is combined with Fluphenazine.]
[N05CD01, flurazepam, Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Methadone is combined with Fluspirilene.]
[L02BB01, flutamide, Methadone may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Methadone which could result in a higher serum level.]
[S02AA17, fosfomycin, Methadone may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L01BC03, tegafur, Methadone may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Methadone is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of serotonin syndrome can be increased when Furazolidone is combined with Methadone.]
[J05AE10, darunavir, The serum concentration of Methadone can be decreased when it is combined with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Furosemide can be decreased when used in combination with Methadone.]
[N05CF04, eszopiclone, The risk or severity of adverse effects can be increased when Methadone is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Methadone is combined with Amisulpride.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Methadone.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Methadone is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Methadone.]
[S01AD09, ganciclovir, Methadone may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Methadone is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Methadone is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Methadone can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Methadone is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Methadone.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Methadone.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Methadone is combined with Cabergoline.]
[J05AG04, etravirine, The metabolism of Methadone can be decreased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Methadone is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Methadone is combined with Alfentanil.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Methadone.]
[A06AH02, alvimopan, The risk or severity of adverse effects can be increased when Methadone is combined with Alvimopan.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Methadone.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Methadone.]
[A10BB07, glipizide, Methadone may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Methadone is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Methadone is combined with Glutethimide.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Methadone.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Methadone.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Methadone.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Methadone.]
[C07AB09, esmolol, The metabolism of Esmolol can be decreased when combined with Methadone.]
[M01CB04, aurothioglucose, Methadone may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Methadone may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Methadone is combined with Fluindione.]
[C09AA09, fosinopril, Methadone may decrease the excretion rate of Fosinopril which could result in a higher serum level.]
[S01EX01, guanethidine, Methadone may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Methadone.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Methadone is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of adverse effects can be increased when Methadone is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Methadone is combined with Halothane.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Methadone.]
[N05AH04, quetiapine, The risk or severity of adverse effects can be increased when Methadone is combined with Quetiapine.]
[N06BX13, idebenone, Methadone may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Methadone is combined with Iprazochrome.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Methadone.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Methadone is combined with Allobarbital.]
[M04AA01, allopurinol, Methadone may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, The metabolism of Methadone can be decreased when combined with Losartan.]
[S01XA14, heparin, The therapeutic efficacy of Heparin can be decreased when used in combination with Methadone.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Methadone.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Methadone.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Methadone which could result in a higher serum level.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Methadone.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Methadone is combined with Hexobarbital.]
[J05AG01, nevirapine, The metabolism of Methadone can be increased when combined with Nevirapine.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Methadone is combined with Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may decrease the excretion rate of Methadone which could result in a higher serum level.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Methadone is combined with Oxatomide.]
[C09AA04, perindopril, Methadone may decrease the excretion rate of Perindopril which could result in a higher serum level.]
[C02DB02, hydralazine, Methadone may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[R05DA03, hydrocodone, The risk or severity of adverse effects can be increased when Methadone is combined with Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Methadone can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Methadone may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[G04BD06, propiverine, The risk or severity of adverse effects can be increased when Propiverine is combined with Methadone.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Methadone.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Methadone is combined with Prothipendyl.]
[B05AA07, hetastarch, Methadone may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Methadone is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Methadone can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Methadone which could result in a higher serum level.]
[B05XA08, sodium acetate, Methadone may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Methadone.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Methadone.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Methadone.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Methadone is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of adverse effects can be increased when Methadone is combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Methadone.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Methadone is combined with Terlipressin.]
[R01AD07, tixocortol, Methadone may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Methadone is combined with Tizanidine.]
[L01CE01, topotecan, Methadone may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, Indomethacin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[A11HA07, inositol, Methadone may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The serum concentration of Methadone can be increased when it is combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The serum concentration of Methadone can be increased when it is combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Methadone is combined with Milnacipran.]
[A03AA30, piperidolate, The risk or severity of adverse effects can be increased when Piperidolate is combined with Methadone.]
[S01XA28, varenicline, Methadone may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Methadone is combined with Articaine.]
[A10BH01, sitagliptin, Methadone may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Methadone is combined with Ramelteon.]
[R06AE01, buclizine, The risk or severity of adverse effects can be increased when Buclizine is combined with Methadone.]
[C10AA06, cerivastatin, The metabolism of Methadone can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Methadone is combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Methadone is combined with Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB09, interferon alfacon-1, The serum concentration of Methadone can be increased when it is combined with Interferon alfacon-1.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Methadone.]
[J05AF04, stavudine, The serum concentration of Stavudine can be decreased when it is combined with Methadone.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Methadone is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of serotonin syndrome can be increased when Iproniazid is combined with Methadone.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Methadone is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of serotonin syndrome can be increased when Isocarboxazid is combined with Methadone.]
[P01AX06, atovaquone, The metabolism of Methadone can be decreased when combined with Atovaquone.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Methadone is combined with Isoflurane.]
[S01EB07, isoflurophate, The therapeutic efficacy of Methadone can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Methadone is combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Methadone can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Methadone may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The therapeutic efficacy of Methadone can be decreased when used in combination with Isoprenaline.]
[C01DA14, isosorbide mononitrate, Methadone may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, Methadone may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Methadone is combined with Reboxetine.]
[S01AA24, kanamycin, Methadone may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The metabolism of Methadone can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Methadone is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Methadone is combined with Ketanserin.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Methadone.]
[J02AB02, ketoconazole, The metabolism of Methadone can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Methadone can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Methadone is combined with Olanzapine.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L04AA24, abatacept, The metabolism of Methadone can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Methadone is combined with Mizolastine.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Methadone is combined with Rotigotine.]
[D10AX03, azelaic acid, Methadone may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Methadone.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Amantadine is combined with Methadone.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Methadone.]
[N07AA30, ambenonium, The therapeutic efficacy of Methadone can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Methadone.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Methadone is combined with Lacosamide.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Methadone is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Methadone is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Methadone.]
[S01AA21, amikacin, Methadone may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Methadone can be decreased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Methadone.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Methadone is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Methadone is combined with Lofepramine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Methadone is combined with Loperamide.]
[N05BA06, lorazepam, Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Methadone.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Methadone is combined with Loxapine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Methadone.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Methadone.]
[B05XA11, magnesium chloride, Methadone may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Methadone.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Methadone.]
[V04CC02, magnesium sulfate, The risk or severity of adverse effects can be increased when Methadone is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Methadone may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Methadone can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The risk or severity of adverse effects can be increased when Methadone is combined with Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Methadone is combined with Mazindol.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Methadone.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Methadone can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Methadone is combined with Meclizine.]
[M02AA18, meclofenamic acid, The therapeutic efficacy of Meclofenamic acid can be decreased when used in combination with Methadone.]
[N05BA03, medazepam, Medazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Methadone.]
[P01BC02, mefloquine, The therapeutic efficacy of Methadone can be decreased when used in combination with Mefloquine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Methadone is combined with Melatonin.]
[N06DX01, memantine, The risk or severity of adverse effects can be increased when Methadone is combined with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Methadone is combined with Meperidine.]
[C01CA11, mephentermine, Mephentermine may increase the analgesic activities of Methadone.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Methadone is combined with Mephenytoin.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methadone is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Methadone is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Methadone is combined with Meprobamate.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Methadone is combined with Meptazinol.]
[G04BX16, tiopronin, Methadone may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[L02BG01, aminoglutethimide, The serum concentration of Methadone can be increased when it is combined with Aminoglutethimide.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Methadone is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Methadone is combined with Paliperidone.]
[A10BA02, metformin, Metformin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Methadone is combined with Dolasetron.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Methadone.]
[N07XX04, sodium oxybate, Methadone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[C01DA05, pentaerythritol tetranitrate, Methadone may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Methadone is combined with Nalidixic acid.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Methadone is combined with Metamfetamine.]
[A03AB07, methantheline, The risk or severity of adverse effects can be increased when Methantheline is combined with Methadone.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Methadone is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Methadone is combined with Methaqualone.]
[J05AF05, lamivudine, Methadone may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Methadone is combined with Metharbital.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Methadone is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Methadone can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Methadone may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methadone is combined with Methocarbamol.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methadone is combined with Methohexital.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Methadone is combined with Ziconotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Methadone.]
[N05AA02, methotrimeprazine, The risk or severity of adverse effects can be increased when Methadone is combined with Methotrimeprazine.]
[D05BA02, methoxsalen, Methadone may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methadone is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Methadone.]
[C02AB01, methyldopa, Methadone may decrease the excretion rate of Methyldopa which could result in a higher serum level.]
[V04CG05, methylene blue, The risk or severity of serotonin syndrome can be increased when Methylene blue is combined with Methadone.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Methadone.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Methadone is combined with Rufinamide.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be decreased when combined with Methadone.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methadone is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methadone is combined with Methysergide.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Methadone.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, The metabolism of Methadone can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The metabolism of Methadone can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, Methadone may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Methadone.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Methadone is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Methadone can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Methadone.]
[N05CD08, midazolam, Midazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Methadone is combined with Mifepristone.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Methadone.]
[J05AH01, zanamivir, Methadone may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The metabolism of Methadone can be decreased when combined with Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[L01XX23, mitotane, The metabolism of Methadone can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may increase the analgesic activities of Methadone.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Methadone is combined with Molindone.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C01BD01, amiodarone, The metabolism of Methadone can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of adverse effects can be increased when Methadone is combined with Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Methadone is combined with Morphine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Methadone is combined with Palonosetron.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Methadone which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Methadone can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, Methadone may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Methadone.]
[L04AA06, mycophenolic acid, Methadone may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Methadone is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Methadone is combined with Amobarbital.]
[P01BA06, amodiaquine, The metabolism of Methadone can be decreased when combined with Amodiaquine.]
[G03XC01, raloxifene, The metabolism of Methadone can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, The risk or severity of adverse effects can be increased when Methadone is combined with Amoxapine.]
[N03AB05, fosphenytoin, The risk or severity of adverse effects can be increased when Methadone is combined with Fosphenytoin.]
[C07AA12, nadolol, The metabolism of Nadolol can be decreased when combined with Methadone.]
[J01CA04, amoxicillin, Methadone may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[N04BC04, ropinirole, Methadone may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Methadone is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Methadone is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Methadone can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Methadone is combined with Naltrexone.]
[L04AC03, anakinra, The metabolism of Methadone can be increased when combined with Anakinra.]
[S01GA01, naphazoline, Naphazoline may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[N06BA01, amphetamine, Amphetamine may increase the analgesic activities of Methadone.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Methadone which could result in a higher serum level.]
[A10BG01, troglitazone, The metabolism of Methadone can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Methadone is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Methadone is combined with Tolcapone.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Methadone.]
[L02BG04, letrozole, The serum concentration of Methadone can be increased when it is combined with Letrozole.]
[S03AA01, neomycin, Methadone may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Methadone is combined with Remifentanil.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Methadone is combined with Levosimendan.]
[B01AC17, tirofiban, Methadone may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[S01EB06, neostigmine, The therapeutic efficacy of Methadone can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Methadone is combined with Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Methadone which could result in a higher serum level.]
[S01AA19, ampicillin, Methadone may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Methadone may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Methadone may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Methadone is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The metabolism of Methadone can be decreased when combined with Telmisartan.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C01CE01, inamrinone, Methadone may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The metabolism of Methadone can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of serotonin syndrome can be increased when Nialamide is combined with Methadone.]
[C08CA04, nicardipine, The risk or severity of adverse effects can be increased when Nicardipine is combined with Methadone.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Methadone.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Methadone.]
[N07BA01, nicotine, The metabolism of Methadone can be decreased when combined with Nicotine.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Methadone is combined with Nifedipine.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Methadone is combined with Nimodipine.]
[C08CA07, nisoldipine, Methadone may decrease the excretion rate of Nisoldipine which could result in a higher serum level.]
[N05CD02, nitrazepam, Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Methadone.]
[R07AX01, nitric oxide, Methadone may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, The therapeutic efficacy of Nitrofurantoin can be decreased when used in combination with Methadone.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Methadone is combined with Zaleplon.]
[N04BC05, pramipexole, Methadone may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Methadone is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Methadone is combined with Nomifensine.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Methadone.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Methadone.]
[C02KX01, bosentan, The metabolism of Methadone can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The risk or severity of adverse effects can be increased when Methadone is combined with Nortriptyline.]
[R05DA07, noscapine, The metabolism of Methadone can be decreased when combined with Noscapine.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Methadone.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Methadone is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Methadone can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Methadone can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Methadone is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Methadone is combined with Opium.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Methadone.]
[J01CF04, oxacillin, Methadone may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[P02BA02, oxamniquine, The metabolism of Methadone can be decreased when combined with Oxamniquine.]
[A14AA08, oxandrolone, The metabolism of Methadone can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Methadone.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Methadone is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Methadone is combined with Oxycodone.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Methadone is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Methadone is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Methadone which could result in a higher serum level.]
[A03AB03, oxyphenonium, The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Methadone.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methadone.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Methadone is combined with Asenapine.]
[N02AX06, tapentadol, The risk or severity of adverse effects can be increased when Methadone is combined with Tapentadol.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Methadone is combined with Pancuronium.]
[J04AB30, capreomycin, Methadone may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Methadone is combined with Papaverine.]
[N05CC05, paraldehyde, The risk or severity of adverse effects can be increased when Methadone is combined with Paraldehyde.]
[C02KC01, pargyline, The risk or severity of serotonin syndrome can be increased when Pargyline is combined with Methadone.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Methadone.]
[G04BD11, fesoterodine, The risk or severity of adverse effects can be increased when Fesoterodine is combined with Methadone.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Methadone is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Methadone is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Methadone may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Methadone is combined with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Methadone is combined with Pentobarbital.]
[L01XX08, pentostatin, Methadone may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Methadone may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Methadone is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Methadone is combined with Pergolide.]
[C08EX02, perhexiline, The metabolism of Methadone can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Methadone is combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Methadone.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Methadone is combined with Phenazocine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N06AF03, phenelzine, The risk or severity of serotonin syndrome can be increased when Phenelzine is combined with Methadone.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Methadone.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Methadone is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Methadone.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Methadone is combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Methadone.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Methadone is combined with Phenoperidine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Methadone.]
[A08AA01, phentermine, Phentermine may increase the analgesic activities of Methadone.]
[V03AB36, phentolamine, Methadone may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, The metabolism of Methadone can be decreased when combined with Phenylbutazone.]
[A02BC06, dexlansoprazole, The metabolism of Methadone can be decreased when combined with Dexlansoprazole.]
[N03AB02, phenytoin, The risk or severity of adverse effects can be increased when Methadone is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Methadone can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Methadone is combined with Levofloxacin.]
[V03AB19, physostigmine, The therapeutic efficacy of Methadone can be decreased when used in combination with Physostigmine.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Methadone.]
[B02BA01, vitamin K1, Methadone may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Methadone which could result in a higher serum level.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Methadone is combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Methadone is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Methadone is combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Methadone.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Methadone can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Methadone.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Methadone is combined with Pipotiazine.]
[N06BX03, piracetam, Methadone may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[A02BX03, pirenzepine, The risk or severity of adverse effects can be increased when Pirenzepine is combined with Methadone.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Methadone is combined with Piritramide.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Methadone which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Methadone is combined with Grepafloxacin.]
[N02CX01, pizotyline, The risk or severity of adverse effects can be increased when Methadone is combined with Pizotifen.]
[J05AG02, delavirdine, The metabolism of Methadone can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Methadone.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Methadone is combined with Proxibarbal.]
[A10BG02, rosiglitazone, Methadone may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[L02BG03, anastrozole, The serum concentration of Methadone can be increased when it is combined with Anastrozole.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methadone.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Methadone is combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Methadone can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The serum concentration of Methadone can be decreased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, Methadone may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Methadone may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Methadone.]
[C07AB01, practolol, The metabolism of Practolol can be decreased when combined with Methadone.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Methadone.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Methadone.]
[H02AB07, prednisone, Methadone may decrease the excretion rate of Prednisone which could result in a higher serum level.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Methadone is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Methadone is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Methadone is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Methadone can be decreased when combined with Primaquine.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Methadone is combined with Primidone.]
[M04AB01, probenecid, The metabolism of Methadone can be decreased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Methadone is combined with Probucol.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Methadone.]
[S01HA05, procaine, The risk or severity of serotonin syndrome can be increased when Procaine is combined with Methadone.]
[L01XB01, procarbazine, The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Methadone.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be decreased when combined with Methadone.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Methadone is combined with Prochlorperazine.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Procyclidine is combined with Methadone.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Methadone.]
[N05AA03, promazine, The risk or severity of adverse effects can be increased when Methadone is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of adverse effects can be increased when Methadone is combined with Promethazine.]
[C01BC03, propafenone, The metabolism of Methadone can be decreased when combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Methadone is combined with Propanidid.]
[A03AB05, propantheline, The risk or severity of adverse effects can be increased when Propantheline is combined with Methadone.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Methadone is combined with Periciazine.]
[N05CM06, propiomazine, The risk or severity of adverse effects can be increased when Methadone is combined with Propiomazine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Methadone.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Methadone is combined with Propofol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Methadone is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Propranolol can be decreased when combined with Methadone.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Methadone is combined with Rizatriptan.]
[B01AC09, epoprostenol, Methadone may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Methadone.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Methadone is combined with Protriptyline.]
[R01BA02, pseudoephedrine, Pseudoephedrine may increase the analgesic activities of Methadone.]
[N05AX12, aripiprazole, The risk or severity of adverse effects can be increased when Methadone is combined with Aripiprazole.]
[N07XX07, dalfampridine, Methadone may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[A03AB15, diphemanil, The risk or severity of adverse effects can be increased when Diphemanil is combined with Methadone.]
[A03AB09, isopropamide, The risk or severity of adverse effects can be increased when Isopropamide is combined with Methadone.]
[S01FA03, methscopolamine, The risk or severity of adverse effects can be increased when Methscopolamine is combined with Methadone.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Methadone is combined with Talbutal.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Methadone is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Methadone is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Methadone is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Methadone is combined with Pyrantel.]
[J04AK01, pyrazinamide, Methadone may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Methadone can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Methadone is combined with Mepyramine.]
[C01BA01, quinidine, The risk or severity of adverse effects can be increased when Quinidine is combined with Methadone.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Methadone is combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Methadone can be decreased when combined with Ranitidine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Methadone is combined with Reserpine.]
[J05AP01, ribavirin, Methadone may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Methadone can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Methadone is combined with Oxitriptan.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Methadone is combined with Roxithromycin.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Methadone which could result in a higher serum level.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the excretion rate of Methadone which could result in a higher serum level.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Methadone which could result in a higher serum level.]
[S01FA02, scopolamine, The risk or severity of adverse effects can be increased when Methadone is combined with Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Methadone is combined with Secobarbital.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Methadone.]
[N04BD01, selegiline, The risk or severity of serotonin syndrome can be increased when Selegiline is combined with Methadone.]
[J01GB08, sisomicin, Methadone may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Methadone may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Methadone.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Methadone.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Methadone.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Methadone.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[N06AF04, tranylcypromine, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[S01AE07, moxifloxacin, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[L01XX27, arsenic trioxide, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[S03AA07, ciprofloxacin, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[L01XA03, oxaliplatin, QT prolonging agents - QT prolonging agents]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[C01BA03, disopyramide, QT prolonging agents - QT prolonging agents]
[A03FA03, domperidone, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[S01AA17, erythromycin, QT prolonging agents - QT prolonging agents]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[N05AD01, haloperidol, QT prolonging agents - QT prolonging agents]
[P01BA02, hydroxychloroquine, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[N06AF01, isocarboxazid, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N05AA02, methotrimeprazine, QT prolonging agents - QT prolonging agents]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[N06AF03, phenelzine, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
[S01AE05, levofloxacin, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[C01BA02, procainamide, QT prolonging agents - QT prolonging agents]
[L01XB01, procarbazine, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
[N01AX10, propofol, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
[N04BD01, selegiline, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
[C07AA07, sotalol, QT prolonging agents - QT prolonging agents]
